Promising New Pill for Pancreatic Cancer Shows Significant Survival Benefits
A new pancreatic cancer pill may be a game changer for patients
Science News
Image: Science News
An experimental drug, daraxonrasib, has shown promise in extending survival for patients with advanced pancreatic cancer, nearly doubling the median survival time compared to traditional chemotherapy. While it offers hope, experts caution that it is not a cure and highlight the need for further research.
- 01Daraxonrasib increased the median survival time for patients to 13 months, compared to less than 7 months with chemotherapy.
- 02The drug works by blocking malfunctioning RAS proteins that promote tumor growth, acting as a molecular glue.
- 03In a Phase III trial with 500 patients, daraxonrasib was associated with fewer severe side effects than chemotherapy, with only 1% discontinuing due to adverse effects.
- 04The U.S. FDA has not yet approved daraxonrasib but has allowed expanded access for seriously ill patients.
- 05Experts believe daraxonrasib could change treatment practices for pancreatic cancer, although it is not a definitive cure.
Advertisement
In-Article Ad
Daraxonrasib, an experimental drug for pancreatic cancer, has shown significant promise, nearly doubling the survival time of patients with advanced disease compared to traditional chemotherapy. Reported at the American Society of Clinical Oncology meeting, the drug helped half of the patients live 13 months or longer, a notable improvement from the median survival of under seven months with chemotherapy. This drug targets malfunctioning RAS proteins, which are implicated in tumor growth, using a unique mechanism that acts like molecular glue. In a Phase III clinical trial involving 500 patients, daraxonrasib demonstrated a better side effect profile than chemotherapy, with only 1% of patients stopping treatment due to adverse effects. While it offers hope for patients with limited options, experts emphasize that it is not a cure for pancreatic cancer, a notoriously deadly disease with a low five-year survival rate. The FDA has not yet approved the drug but has permitted expanded access for critically ill patients, indicating its potential to significantly alter treatment approaches in the future.
Advertisement
In-Article Ad
The introduction of daraxonrasib could significantly improve treatment outcomes for pancreatic cancer patients, providing them with a new option in a field with limited therapies.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of daraxonrasib for treating pancreatic cancer?
Connecting to poll...
Read the original article
Visit the source for the complete story.